alnylam is across the street from genzyme. and this model gives us access to a portfolio of new treatments for rare diseases. but it's also, i think, different model in the sense that you know, alnylam also announced an acquisition of patents from a company called cerna that merck acquired. the technology always hasn't done that well. so this is an opportunity for us to participate as a partner, shareholder, but to also leave alnylam not only as an autonomous company but grow from being research and development company to fully-fledged, integrated commercial company. that's the logic behind that. >> is that a new strategy in the sense of, many offo our viewers recall the large acquisition of genzyme. are those deals not going to happen in the future, as opposed to replaced with the like of this transaction or your ownership in regeneron, for example. >> it was the model for this transaction. soed, sano today, sanofi has one of the top five pipelines in the industry today. a large coming from regenero. there's a positive relati